FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 311:491-495 August 23, 1984 Number 8 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We retrospectively studied the evolution of histopathologic features in successive renal biopsies in patients with lupus nephritis, to evaluate the effects of various treatment regimens. Repeat renal biopsies had been performed in 62 patients after more than 18 months of observation (median interval, 44 months) in randomized therapeutic trials comparing prednisone with cytotoxic drugs. Renal histopathologic features were graded individually, and a composite score reflecting the number and severity of irreversible lesions was defined as a chronicity index. The chronicity index for patients treated with conventional high-dose prednisone increased linearly with the interval between biopsies, whereas the index in the group receiving cytotoxic-drug treatments did not increase over time. After statistical adjustment for important prognostic factors (age and initial chronicity index) identified by multiple linear regression, the difference in the slopes between the group receiving prednisone and the group receiving cytotoxic drugs was significant (P less than 0.0001). We conclude that cytotoxic-drug treatment reduces the likelihood of progressive renal scarring in lupus nephritis.

This article has been cited by other articles:

• Kimura, H., Li, X., Torii, K., Okada, T., Kamiyama, K., Mikami, D., Takahashi, N., Yoshida, H. (2009). Dexamethasone enhances basal and TNF-{alpha}-stimulated production of PAI-1 via the glucocorticoid receptor regardless of 11{beta}-hydroxysteroid dehydrogenase 2 status in human proximal renal tubular cells. Nephrol Dial Transplant 24: 1759-1765 [Abstract] [Full Text]  
• Bargman, J. M. (2009). How did cyclophosphamide become the drug of choice for lupus nephritis?. Nephrol Dial Transplant 24: 381-384 [Full Text]  
• Bertsias, G, Ioannidis, J P A, Boletis, J, Bombardieri, S, Cervera, R, Dostal, C, Font, J, Gilboe, I M, Houssiau, F, Huizinga, T, Isenberg, D, Kallenberg, C G M, Khamashta, M, Piette, J C, Schneider, M, Smolen, J, Sturfelt, G, Tincani, A, van Vollenhoven, R, Gordon, C, Boumpas, D T (2008). EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67: 195-205 [Abstract] [Full Text]  
• de Castro, W.P., Morales, J.V., Wagner, M.B., Graudenz, M., Edelweiss, M.I., Goncalves, L.F. (2007). Hypertension and Afro-descendant ethnicity: a bad interaction for lupus nephritis treated with cyclophosphamide?. Lupus 16: 724-730 [Abstract]  
• Okada, H., Kikuta, T., Inoue, T., Kanno, Y., Ban, S., Sugaya, T., Takigawa, M., Suzuki, H. (2006). Dexamethasone Induces Connective Tissue Growth Factor Expression in Renal Tubular Epithelial Cells in a Mouse Strain-Specific Manner. Am. J. Pathol. 168: 737-747 [Abstract] [Full Text]  
• Williams, W, Bhagwandass, A, Sargeant, L A, Shah, D (2003). Severity of systemic lupus erythematosus with diffuse proliferative glomerulonephritis and the ineffectiveness of standard pulse intravenous cyclophosphamide therapy in Jamaican patients. Lupus 12: 640-645 [Abstract]  
• Stallmach, A, Wittig, B M, Moser, C, Fischinger, J, Duchmann, R, Zeitz, M (2003). Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Gut 52: 377-382 [Abstract] [Full Text]  
• MACHOLD, K P, SMOLEN, J S (2001). Stem cell transplantation: limits and hopes. Ann Rheum Dis 60: 548-549 [Full Text]  
• Amano, H, Morimoto, S, Kaneko, H, Tokano, Y, Takasaki, Y, Hashimoto, H (2000). Effect of intravenous cyclophosphamide in systemic lupus erythematosus: relation to lymphocyte subsets and activation markers. Lupus 9: 26-32 [Abstract]  
• CAMERON, J. S. (1999). Lupus Nephritis. J. Am. Soc. Nephrol. 10: 413-424 [Full Text]  
• Mittal, G, Balakrishna, C, Mangat, G, Joshi, V R (1999). 'Sustained remission' in a case of SLE following megadose cyclophosphamide. Lupus 8: 77-80 [Abstract]  
• Grande, J P, Balow, J E (1998). Renal biopsy in lupus nephritis. Lupus 7: 611-617 [Abstract]  
• Boumpas, D T, Balow, J E (1998). Outcome criteria for lupus nephritis trials: A critical overview. Lupus 7: 622-629 [Abstract]  
• Dooley, M A, Falk, R J (1998). Immunosuppressive therapy of lupus nephritis. Lupus 7: 630-634 [Abstract]  
• Gloor, J M (1998). Lupus nephritis in children. Lupus 7: 639-643 [Abstract]  
• Hricik, D. E., Chung-Park, M., Sedor, J. R. (1998). Glomerulonephritis. NEJM 339: 888-899 [Full Text]  
• Martin-Suarez, I., D'Cruz, D., Mansoor, M., Fernandes, A. P., Khamashta, M. A, Hughes, G. R V (1997). Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 56: 481-487 [Abstract] [Full Text]  
• Belmont, H M., Storch, M., Buyon, J., Abramson, S. (1995). New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 4: 104-108 [Abstract]  
• Sesso, R., Monteiro, M., Sato, E., Kirsztajn, G., Silva, L., Ajzen, H. (1994). A Controlled Trial of Pulse Cydophosphamide Versus Pulse Methylprednisolone in Severe Lupus Nephritis. Lupus 3: 107-112 [Abstract]  
• Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., Fauci, A. S. (1992). Wegener Granulomatosis: An Analysis of 158 Patients. ANN INTERN MED 116: 488-498 [Abstract]  
• Derksen, R. H.W.M., Hene, R. J., Kater, L. (1992). The Long-Term Clinical Outcome of 56 Patients with Biopsy-Proven Lupus Nephritis Followed at a Single Center. Lupus 1: 97-103 [Abstract]  
• Houssiau, F.A., D'Cruz, D.P., Haga, H.-J., Hughes, G.R.V. (1991). Short Course of Weekly Low-Dose Intravenous Pulse Cyclophosphamide in the Treatment of Lupus Nephritis: A Preliminary Study. Lupus 1: 31-35 [Abstract]  
• STROBER, S., FARINAS, M. C., FIELD, E. H., SOLOVERA, J. J., KIBERD, B. A., MYERS, B. D., HOPPE, R. T. (1987). Lupus Nephritis After Total Lymphoid Irradiation: Persistent Improvement and Reduction of Steroid Therapy. ANN INTERN MED 107: 689-690 [Abstract]  
• BALOW, J. E., AUSTIN, H. A. III, TSOKOS, G. C., ANTONOVYCH, T. T., STEINBERG, A. D., KLIPPEL, J. H. (1987). Lupus Nephritis. ANN INTERN MED 106: 79-94 [Abstract]